MedTrace Logo

A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects

NCT03493698 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2020-10-08

Study results available
· View outcomes & findings →

Summary

This is a single center, open-label, fixed sequence study to investigate the effect of multiple oral dosing of Inarigivir Soproxil and a single oral dose of Midazolam in Healthy Subjects

Conditions

  • Drug Interaction Potentiation

Interventions

DRUG

Midazolam

Midazolam

DRUG

Inarigivir

Inarigivir

Sponsors & Collaborators

  • PRA Health Sciences

    collaborator INDUSTRY

  • F-star Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jeroen van de Wetering · PRA Health Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-07
Primary Completion
2018-08-27
Completion
2018-08-27

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03493698 on ClinicalTrials.gov